225 related articles for article (PubMed ID: 21698538)
1. [A comprehensive assessment of ATMP. Difficulties and approaches].
Thanner M; Nagel E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):843-8. PubMed ID: 21698538
[TBL] [Abstract][Full Text] [Related]
2. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
Reiss M; Büttel IC; Schneider CK
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
[TBL] [Abstract][Full Text] [Related]
3. [Advanced therapy medicinal products : Scientific, medical, economic, and ethical aspects].
Seitz R; Schneider CK; Hengel H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):789-90. PubMed ID: 21698529
[No Abstract] [Full Text] [Related]
4. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
Buljovčić Z
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
[TBL] [Abstract][Full Text] [Related]
5. Compassionate use of experimental therapies: who should decide?
Zettler PJ
EMBO Mol Med; 2015 Oct; 7(10):1248-50. PubMed ID: 26202382
[TBL] [Abstract][Full Text] [Related]
6. [The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises].
Berger A; Schüle S; Flory E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):816-21. PubMed ID: 21698534
[TBL] [Abstract][Full Text] [Related]
7. [Clinical trials with advanced therapy medicinal products].
Schüssler-Lenz M; Schneider CK
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):68-74. PubMed ID: 20011994
[TBL] [Abstract][Full Text] [Related]
8. The advanced therapy classification procedure. Overview of experience gained so far.
Voltz-Girolt C; Celis P; Boucaumont M; D'Apote L; Pinheiro MH; Papaluca-Amati M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):811-5. PubMed ID: 21698533
[TBL] [Abstract][Full Text] [Related]
9. [The Innovation Office of the Paul-Ehrlich-Institut. Regulatory support during the scientific development of ATMP].
Ziegele B; Dahl L; Müller AT
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):857-66. PubMed ID: 21698540
[TBL] [Abstract][Full Text] [Related]
10. [Regulatory framework of innovative therapies : From bench to bedside].
Walter C; Rohde B; Wicke DC; Pohler C; Lührmann A; von der Leyen H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):803-10. PubMed ID: 21698532
[TBL] [Abstract][Full Text] [Related]
11. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
Bakopoulou A
J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
[TBL] [Abstract][Full Text] [Related]
12. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
Dwenger A; Strassburger J; Schwerdtfeger W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
[TBL] [Abstract][Full Text] [Related]
13. [From basic research to the clinic. Regulations for preclinical and clinical studies with stem cells].
Steinhoff G; Tiedemann G; Thalheimer M; Ho AD
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Sep; 51(9):973-9. PubMed ID: 18773175
[TBL] [Abstract][Full Text] [Related]
14. From discovery to approval of an advanced therapy medicinal product-containing stem cells, in the EU.
Pellegrini G; Lambiase A; Macaluso C; Pocobelli A; Deng S; Cavallini GM; Esteki R; Rama P
Regen Med; 2016 Jun; 11(4):407-20. PubMed ID: 27091398
[TBL] [Abstract][Full Text] [Related]
15. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
Kuhlmann-Gottke J; Duchow K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
[TBL] [Abstract][Full Text] [Related]
16. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
Kočí Z; Boráň T; Krůpa P; Kubinová Š
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
[TBL] [Abstract][Full Text] [Related]
17. European Medicines Agency, CAT Secretariat & US Food and Drug Administration.
Regen Med; 2011 Nov; 6(6 Suppl):90-6. PubMed ID: 21999268
[TBL] [Abstract][Full Text] [Related]
18. Participation of patients in the development of advanced therapy medicinal products.
Bignami F; Kent AJ; Lipucci di Paola M; Meade N
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):839-42. PubMed ID: 21698537
[TBL] [Abstract][Full Text] [Related]
19. Translational research on advanced therapies.
Belardelli F; Rizza P; Moretti F; Carella C; Galli MC; Migliaccio G
Ann Ist Super Sanita; 2011; 47(1):72-8. PubMed ID: 21430343
[TBL] [Abstract][Full Text] [Related]
20. [Requirements for long-term follow-up on efficacy and safety of advanced therapy medicinal products. Risk management and traceability].
Klug B; Reinhardt J; Schröder C
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):58-62. PubMed ID: 19949763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
